Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 39.26 +0.45 (+1.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > 2 Cathie Wood Biotech Stocks That Could Be Worth the Risk May 29, 2024 You don't need to buy her picks, but it's worth understanding them. Via The Motley Fool FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation May 29, 2024 From Genentech Via Business Wire If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today May 26, 2024 What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised. Via The Motley Fool Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies May 23, 2024 U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq. Via Benzinga Topics Lawsuit Exposures Financial Legal This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan May 21, 2024 The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. Via Benzinga FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation May 21, 2024 From Genentech Via Business Wire Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate May 16, 2024 Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with... Via Benzinga Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity May 16, 2024 From Genentech Via Business Wire Can Ocugen Stock Keep Churning Higher? April 29, 2024 This tiny biotech caught fire in 2024. Can it sustain the momentum? Via The Motley Fool Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? April 24, 2024 HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... Via Benzinga Exposures Product Safety 2 Small-Cap Growth Stocks With Room To Run April 24, 2024 These two small-cap growth stocks could be ready to run. Via The Motley Fool FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer April 18, 2024 From Genentech Via Business Wire Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS April 17, 2024 From Genentech Via Business Wire Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients April 15, 2024 Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. Via Benzinga Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study April 15, 2024 From Genentech Via Business Wire Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. April 14, 2024 Think globally with this high-yielding ETF. Via The Motley Fool Topics ETFs Why Roche Holdings Stock Popped Today April 11, 2024 Roche's new Alzheimer's test has a long road ahead of it, but it may help boost the pharmaceutical company's slow growth rate. Via The Motley Fool Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. April 10, 2024 Recursion is playing the long game with its AI-focused approach to drug discovery and development. Via The Motley Fool Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data April 08, 2024 The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood... Via Benzinga Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst April 08, 2024 Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. Via Investor's Business Daily Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. Via Investor's Business Daily Exposures Product Safety Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs March 22, 2024 The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. Via InvestorPlace Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? March 21, 2024 Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart... Via Benzinga Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B March 20, 2024 Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to... Via Benzinga FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer March 15, 2024 FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with... Via Benzinga Exposures Product Safety Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' March 11, 2024 Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. Via Benzinga Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates March 09, 2024 This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... Via Talk Markets Exposures Product Safety FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer March 08, 2024 FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at... Via Benzinga Exposures Product Safety Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges March 05, 2024 Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event. Via Benzinga 11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields February 28, 2024 A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
